These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Chowdhury FU; Bradley KM; Gleeson FV Clin Radiol; 2008 Dec; 63(12):1297-309. PubMed ID: 18996259 [TBL] [Abstract][Full Text] [Related]
26. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
27. PET and PET-CT in esophageal and gastric cancer. Wieder HA; Krause BJ; Herrmann K Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929 [TBL] [Abstract][Full Text] [Related]
28. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565 [TBL] [Abstract][Full Text] [Related]
29. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas. Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672 [TBL] [Abstract][Full Text] [Related]
30. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156 [TBL] [Abstract][Full Text] [Related]
31. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Bredella MA; Caputo GR; Steinbach LS AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489 [TBL] [Abstract][Full Text] [Related]
33. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351 [TBL] [Abstract][Full Text] [Related]
34. Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET. Guja KE; Ganjoo KN; Iagaru A Semin Nucl Med; 2024 May; 54(3):332-339. PubMed ID: 38433024 [TBL] [Abstract][Full Text] [Related]
35. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125 [TBL] [Abstract][Full Text] [Related]
37. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay. Tewfik JN; Greene GS Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325 [TBL] [Abstract][Full Text] [Related]
38. F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Vasanawala MS; Wang Y; Quon A; Gambhir SS Clin Nucl Med; 2006 Sep; 31(9):534-7. PubMed ID: 16921276 [TBL] [Abstract][Full Text] [Related]
39. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579 [TBL] [Abstract][Full Text] [Related]